Zydus Lifesciences Ltd.

BSE: 532321 | NSE: ZYDUSLIFE

Mid Cap | Pharmaceuticals & Drugs

930.20

1.35 (0.15%)

< Home < Back

Zydus Lifesciences informs about press release

Date: 30-08-2022

Zydus Lifesciences has informed about Press Release dated August 30, 2022 titled 'Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with chronic kidney disease induced anemia'.

The above information is a part of company’s filings submitted to BSE.